Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04207086
Title A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)
Acronym Neo PeLe
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS


No variant requirements are available.